Skip to main content

Arch Biopartners Announces Issuance of U.S. Patent for Dipeptidase-1 Inhibitor Drug for Use in Acute Kidney Injury

Written by Customer Service on . Posted in Public Companies.

TORONTO, Dec. 04, 2019 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today the U.S. Patent and Trademark Office (USPTO) has issued to Arch U.S. Patent number 10,493,127 titled, “Dipeptidase-1 Binding Compositions and Methods of Treatment”.
This is the first patent issued protecting the method of use for the dipeptidase-1 (DPEP-1) inhibitor, cilastatin, for ischemia reperfusion injury, where DPEP-1 mediated inflammation plays a major role.This patent complements the company’s lead drug candidate Metablok (LSALT peptide) and broadens Arch’s portfolio to target organ inflammation via the DPEP-1 pathway.About Metablok and DPEP-1Metablok is a novel peptide drug candidate and the lead DPEP-1 inhibitor in the Arch development pipeline.A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins recently published a paper in the journal Cell describing a novel mechanism of action for organ inflammation. In the publication, DPEP-1 was identified for the first time as a major neutrophil adhesion receptor on the lung, liver and kidney endothelium. This establishes DPEP-1 as a novel therapeutic target for inflammatory diseases of these organs, including sepsis and cardiac surgery-associated acute kidney injury.Under inflammatory conditions, Metablok targets DPEP-1 in the lung, liver and kidney and functionally blocks neutrophil recruitment to these organs.Arch is nearing the end of the Phase I clinical trial for Metablok involving 44 healthy volunteers in Melbourne, Australia. The Phase I trial is a double-blind, placebo-controlled, randomized, single and multiple ascending dose study to evaluate the safety and pharmacokinetic profile of Metablok. An update on the trial will be provided by Arch following the dosing of the 44th volunteer, which is expected shortly.Other Corporate DevelopmentsThe Company also announced today that a director of the Company recently exercised a total of 350,000 stock options to buy 350,000 common shares of the Company for proceeds of $105,000.The Company also announced today that Patrick Vink and Conor Gunne will be vacating their directorships on the Board of the Company and will continue to assist Arch in new roles as Strategic Advisors, effective immediately.  As a result of this change, the number of Arch directors has been reduced to five.“On behalf of Arch, I would like to thank both Mr. Gunne and Mr. Vink for their contributions to our Company as directors and we look forward to continuing to work together in their new roles,” said Richard Muruve, CEO and director of Arch.About Arch BiopartnersArch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.  Arch is developing a drug platform, led by Metablok, to produce new drug candidates that inhibit organ inflammation caused via the DPEP-1 pathway.For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.comThe Company has 59,412,302 common shares outstanding.Forward-Looking StatementsAll statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. 
For more information, please contact:

Richard Muruve
Chief Executive Officer
Arch Biopartners, Inc.
647-428-7031

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.